Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value (Tables)

Fair Value (Tables)

6 Months Ended

Jun. 30, 2018

Schedule of financial assets measured at fair value on a recurring basis

Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands):


	Assets at Fair Value as of June 30, 2018
	Level 1		Level 2		Level 3		Total
Money market funds	$	8,165	$	—	$	—	$	8,165
U.S. treasury bills		—		5,240		—		5,240
Government-sponsored enterprise securities		—		4,184		—		4,184
Corporate bonds and commercial paper		—		116,439		—		116,439
Total	$	8,165	$	125,863	$	—	$	134,028


	Assets at Fair Value as of December 31, 2017
	Level 1		Level 2		Level 3		Total
Money market funds	$	2,795	$	—	$	—	$	2,795
U.S. treasury bills		—		6,726		—		6,726
Government-sponsored enterprise securities		—		7,826		—		7,826
Corporate bonds and commercial paper		—		97,822		—		97,822
Total	$	2,795	$	112,374	$	—	$	115,169